VSee Health, Inc. (VSEE)
NASDAQ: VSEE · Real-Time Price · USD
0.2850
+0.0050 (1.79%)
At close: Mar 9, 2026, 4:00 PM EDT
0.2907
+0.0057 (2.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT
Company Description
VSee Health, Inc. provides telehealth care solutions in the United States.
The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions.
It also provides telehealth software building blocks, such as patient engagement, clinician staffing, remote physical exam and remote patient monitoring, and AI for telesitter and telenursing solutions; data connectors; and workflow templates.
The company distributes its products through third-party resellers and affiliated hospitals, as well as sales executives.
VSee Health, Inc. is headquartered in Newton, Massachusetts.
VSee Health, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 154 |
| CEO | M.D. Dr. Imoigele P. Aisiku M.B.A. |
Contact Details
Address: One Gateway Center, Suite 507 Newton, Massachusetts 02458 United States | |
| Website | vseehealth.com |
Stock Details
| Ticker Symbol | VSEE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1864531 |
| CUSIP Number | 92919Y102 |
| ISIN Number | US92919Y1029 |
| Employer ID | 86-2970927 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Dr. Imoigele P. Aisiku M.B.A., M.D. | Co-Chief Executive Officer and Director |
| Dr. Milton Chen Ph.D. | Co-Chief Executive Officer and Chairman of the Board |
| Jerry Leonard CPA, M.B.A. | Chief Financial Officer, Senior Vice President and Secretary |
| Erika Chuang Ph.D. | Chief of Products |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | 424B3 | Prospectus |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 23, 2026 | SCHEDULE 13G/A | Filing |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 5, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 3, 2026 | SCHEDULE 13G/A | Filing |
| Jan 26, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 8, 2026 | 424B3 | Prospectus |